These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 23682005)

  • 21. Effectiveness of 1 dose of 2009 influenza A (H1N1) vaccine at preventing hospitalization with pandemic H1N1 influenza in children aged 7 months-9 years.
    Hadler JL; Baker TN; Papadouka V; France AM; Zimmerman C; Livingston KA; Zucker JR
    J Infect Dis; 2012 Jul; 206(1):49-55. PubMed ID: 22551808
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immune response to pandemic H1N1 2009 influenza a vaccination in pediatric liver transplant recipients.
    Haller W; Buttery J; Laurie K; Beyerle K; Hardikar W; Alex G
    Liver Transpl; 2011 Aug; 17(8):914-20. PubMed ID: 21351241
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of antigen and adjuvant doses resulting in optimal immunogenicity and antibody persistence up to 1 year after immunization with a pandemic A/H1N1 influenza vaccine in children 3 to < 9 years of age.
    Nassim C; Christensen S; Henry D; Holmes S; Hohenboken M; Kanesa-Thasan N
    Pediatr Infect Dis J; 2012 Apr; 31(4):e59-65. PubMed ID: 22418661
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and immunogenicity of adjuvanted inactivated split-virion and whole-virion influenza A (H5N1) vaccines in children: a phase I-II randomized trial.
    Wu J; Liu SZ; Dong SS; Dong XP; Zhang WL; Lu M; Li CG; Zhou JC; Fang HH; Liu Y; Liu LY; Qiu YZ; Gao Q; Zhang XM; Chen JT; Zhong X; Yin WD; Feng ZJ
    Vaccine; 2010 Aug; 28(38):6221-7. PubMed ID: 20638454
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A 1-year follow-on study from a randomised, head-to-head, multicentre, open-label study of two pandemic influenza vaccines in children.
    de Whalley P; Walker W; Snape MD; Oeser C; Casey M; Moulsdale P; Harrill C; Andrews N; Hoschler K; Thompson B; Jones C; Chalk J; Kerridge S; Tomlinson R; Heath PT; Finn A; Faust S; Miller E; Pollard AJ
    Health Technol Assess; 2011 Dec; 15(45):v-vi, xi-xiii, 1-128. PubMed ID: 22257497
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-lasting immunogenicity and safety of a 2009 pandemic influenza A(H1N1) MF59-adjuvanted vaccine when co-administered with a 2009-2010 seasonal influenza vaccine in young patients with type 1 diabetes mellitus.
    Zuccotti GV; Pariani E; Scaramuzza A; Santoro L; Giani E; Macedoni M; Gazzarri A; Anselmi G; Amendola A; Zanetti A
    Diabet Med; 2011 Dec; 28(12):1530-6. PubMed ID: 21916971
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomized clinical trial to identify the optimal antigen and MF59(®) adjuvant dose of a monovalent A/H1N1 pandemic influenza vaccine in healthy adult and elderly subjects.
    Hatz C; von Sonnenburg F; Casula D; Lattanzi M; Leroux-Roels G
    Vaccine; 2012 May; 30(23):3470-7. PubMed ID: 22446638
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Poor immune response to a standard single dose non-adjuvanted vaccination against 2009 pandemic H1N1 influenza virus A in the adult and elder hemodialysis patients.
    Chang YT; Guo CY; Tsai MS; Cheng YY; Lin MT; Chen CH; Shen D; Wang JR; Sung JM
    Vaccine; 2012 Jul; 30(33):5009-18. PubMed ID: 22658967
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serological response and persistence in schoolchildren with high baseline seropositive rate after receiving 2009 pandemic influenza A(H1N1) vaccine.
    Chao DY; Cheng KF; Hsieh YH; Li TC; Wu TN; Chen CY; Tsai CA; Chen JH; Chiu HT; Lu JJ; Su MC; Liao YH;
    Vaccine; 2011 Jan; 29(4):617-23. PubMed ID: 21095255
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and persistence of immunological response 6 months after intramuscular vaccination with an AS03-adjuvanted H1N1 2009 influenza vaccine: an open-label, randomized trial in Japanese children aged 6 months to 17 years.
    Saitoh A; Nagai A; Tenjinbaru K; Li P; Vaughn DW; Roman F; Kato T
    Hum Vaccin Immunother; 2012 Jun; 8(6):749-58. PubMed ID: 22495117
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessment of the immunogenicity and safety of varying doses of an MF59®-adjuvanted cell culture-derived A/H1N1 pandemic influenza vaccine in Japanese paediatric, adult and elderly subjects.
    Fukase H; Furuie H; Yasuda Y; Komatsu R; Matsushita K; Minami T; Suehiro Y; Yotsuyanagi H; Kusadokoro H; Sawata H; Nakura N; Lattanzi M
    Vaccine; 2012 Jul; 30(33):5030-7. PubMed ID: 22472791
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunogenicity and safety of a monovalent vaccine for the 2009 pandemic influenza virus A (H1N1) in children and adolescents.
    Lu CY; Shao PL; Chang LY; Huang YC; Chiu CH; Hsieh YC; Lin TY; Huang LM
    Vaccine; 2010 Aug; 28(36):5864-70. PubMed ID: 20600484
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effectiveness of vaccine against pandemic influenza A/H1N1 among people with underlying chronic diseases: cohort study, Denmark, 2009-10.
    Emborg HD; Krause TG; Hviid A; Simonsen J; Mølbak K
    BMJ; 2011 Jan; 344():d7901. PubMed ID: 22277542
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The antibody response to pandemic H1N1 2009 influenza vaccine in adult organ transplant patients.
    Felldin M; Studahl M; Svennerholm B; Friman V
    Transpl Int; 2012 Feb; 25(2):166-71. PubMed ID: 22117586
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Response to a monovalent 2009 influenza A (H1N1) vaccine.
    Greenberg ME; Lai MH; Hartel GF; Wichems CH; Gittleson C; Bennet J; Dawson G; Hu W; Leggio C; Washington D; Basser RL
    N Engl J Med; 2009 Dec; 361(25):2405-13. PubMed ID: 19745216
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.
    Leroux-Roels I; Roman F; Forgus S; Maes C; De Boever F; Dramé M; Gillard P; van der Most R; Van Mechelen M; Hanon E; Leroux-Roels G
    Vaccine; 2010 Jan; 28(3):849-57. PubMed ID: 19835828
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A clinical study to assess the immunogenicity and safety of a monovalent 2009 influenza A (H1N1) vaccine in an area with low-level epidemics of pandemic influenza.
    Kung HC; Huang KC; Kao TM; Lee YC; Chang FY; Wang NC; Liu YC; Lee WS; Liu HJ; Chen CI; Chen CH; Huang LM; Hsieh SM
    Vaccine; 2010 Oct; 28(45):7337-43. PubMed ID: 20817013
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effectiveness of pandemic H1N1 vaccine against influenza-related hospitalization in children.
    Gilca R; Deceuninck G; De Serres G; Boulianne N; Sauvageau C; Quach C; Boucher FD; Skowronski DM
    Pediatrics; 2011 Nov; 128(5):e1084-91. PubMed ID: 21987710
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diminished immunogenicity to pandemic H1N1 2009 influenza vaccine in subjects with severe motor and intellectual disability.
    Hara M; Hanaoka T; Mizushima T; Honma J; Maeda K; Ohfuji S; Tanaka K; Hirota Y
    Vaccine; 2011 Oct; 29(46):8323-9. PubMed ID: 21893146
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A randomised, single-blind, dose-range study to assess the immunogenicity and safety of a cell-culture-derived A/H1N1 influenza vaccine in adult and elderly populations.
    Hatz C; Cramer JP; Vertruyen A; Schwarz TF; von Sonnenburg F; Borkowski A; Lattanzi M; Hilbert AK; Cioppa GD; Leroux-Roels G
    Vaccine; 2012 Jul; 30(32):4820-7. PubMed ID: 22626675
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.